IntroductionThe differential diagnosis of early Parkinson's disease (PD) by a single biomarker is still challenging due to its symptomatic overlap with other neurological diseases. Increasing evidences support the use of saliva biomarkers of neurodegeneration, including microRNAs and α-synuclein (α-syn) seeding activity, to diagnose patients with idiopathic PD and multiple system atrophy (MSA). Our previous study confirmed the salivary microRNA-29a-3p (miRNA-29a-3p) and α-syn seeding activity could differentiate PD and MSA from healthy control subjects (HCs) and patients with essential tremor (ET). MethodsWe set up α-syn real-time quaking induced conversion seed amplification assay (α-syn RT-QuIC SAA) in 203 participants from the Peking University First Hospital with PD (n = 101), MSA (n = 32), ET (n = 17) and healthy control subjects (HCs, n = 53). We also determined miRNA-29a-3p in saliva by real time quantitative PCR (RT-qPCR) and, in 155 participants (36HCs, 80PD, 22MSA, 17ET). ResultsSensitivity of RT-QuIC seed amplification assay (SAA) for PD was 70.30 %, for MSA was 56.25 % and specificity for healthy controls was 92.45 %. The expression level of saliva miRNA-29a-3p was significantly decreased in patients with PD (p < 0.001) and MSA (p < 0.0001), and allowed differentiation with HCs (PD vs. HCs, AUC 0.69; MSA vs. HCs, AUC 0.95). Sensitivity of salivary miRNA-29a-3p for PD and MSA were 70.00 % and 95.45 %, respectively, and specificity for PD and MSA were 77.23 % and 80.56 %, respectively. By combining the salivary α-syn RT-QuIC SAA with miRNA-29a-3p, sensitivity for PD vs. HCs increasing to 75.00 %, while sensitivity for MSA vs. HCs increasing to 90.00 %. Specificity was 91.67 % for PD and 88.89 % for MSA after combining assessment of salivary α-syn RT-QuIC SAA. Salivary α-syn RT-QuIC SAA yielded 100.00 % sensitivity and 79.21 % specificity for PD vs. ET, and 100.00 % sensitivity and 65.63 % specificity for MSA vs. ET. Salivary miRNA-29a-3p provied 88.24 % sensitivity and 48.75 % specificity for PD vs. ET and 86.36 % sensitivity and 88.24 % specificity for MSA vs. ET. The combined assessment of saliva markers provided a better diagnostic value for ET vs. synucleinopathies (ET vs. PD: 88.24 % sensitivity and 81.25 % specificity; ET vs. MSA: 94.12 % sensitivity and 90.00 % specificity) than RT-QuIC SAA alone, or miRNA-29a-3p alone. The combination of lag phase and miRNA-29a-3p could add higher specificity (85.71 %) which increased approximately 40 percent (specificity: miRNA-29a-3p 47.50 %, lag phase 48.98 %) for discriminating PD from MSA. However, the sensitivity of combining these two methods was 61.11 %, which was lower than lag phase alone (89.66 %) or miRNA-29a-3p alone (95.45 %). ConclusionsThis study confirmed that saliva, a non-invasive biofluid in synucleinopathies possessed potential diagnostic power between PD, MSA, ET and normal controls. We show the combined value of saliva miRNA-29a-3p and saliva α-syn RT-QuIC SAA in the diagnosis and differential diagnosis of Parkinsonism.
Read full abstract